{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1","value":"0.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"To test if 9-months of treatment with etelcalcetide improves spine BMD, a change in age and sex adjusted Z-Score will be calculated from baseline to 9 months. A Z-Score of zero represent the population mean and higher Z-Scores indicate a better outcome.","dispersionType":"Standard Error","groups":[{"description":"Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.\n\nEtelcalcetide: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.","id":"OG000","title":"Study Participant"}],"paramType":"MEAN","populationDescription":"Only includes participants who completed the study.","reportingStatus":"POSTED","timeFrame":"Baseline and 9 months","title":"Change in Bone Mineral Density (BMD) of the Spine by DXA","type":"SECONDARY","unitOfMeasure":"Z-score"}